Oncogenic CARMA1 mutations driving constitutive signaling activity of the CBM complex have initially been discovered in approximately 10% of patients suffering from the aggressive ABC subtype of DLBCL which relies on constitutive NF-κB signaling for survival and proliferation [137]. The gene discussed is CARD11; the disease is diffuse large B-cell lymphoma.